We are live on
!
Find out more
KAM
Krensavage Asset Management Portfolio holdings
AUM
$256M
1-Year Est. Return
69.63%
This Fund
S&P 500
This Quarter
Est. Return
+8.76%
1 Year Est. Return
+69.63%
3 Year Est. Return
+113.28%
5 Year Est. Return
+196.5%
10 Year Est. Return
+463.27%
AUM
$319M
AUM Growth
+$24.2M
(+8.2%)
Cap. Flow
+$6.39M
Cap. Flow
% of AUM
2%
Top 10 Holdings %
Top 10 Hldgs %
97.56%
Holding
14
New
1
Increased
3
Reduced
9
Closed
1
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Exelixis
EXEL
|
+$18.6M |
| 2 |
Biogen
BIIB
|
+$1.86M |
| 3 |
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
|
+$1.82M |
| 4 |
TARO
Taro Pharmaceutical Industries Ltd.
TARO
|
+$130K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alkermes
ALKS
|
+$6.97M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$5.56M |
| 3 |
United Therapeutics
UTHR
|
+$2.44M |
| 4 |
McKesson
MCK
|
+$369K |
| 5 |
AnaptysBio
ANAB
|
+$282K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Enanta Pharmaceuticals
ENTA
$366M
| $53.2M | 16.69% |
936,777
-2,873
| -0.3% | -$142K |
|
|
2
Alkermes
ALKS
$8.22B
| $44.5M | 13.95% |
1,441,967
-246,874
| -15% | -$6.97M |
|
|
3
Regeneron Pharmaceuticals
REGN
$78.5B
| $44.3M | 13.89% |
73,143
-8,961
| -11% | -$5.56M |
|
|
4
United Therapeutics
UTHR
$25.8B
| $38.3M | 12% |
207,287
-12,403
| -6% | -$2.44M |
|
|
TARO
5
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
| $34.7M | 10.89% |
545,583
+1,878
| +0.3% | +$130K |
|
|
6
McKesson
MCK
$100B
| $32.8M | 10.29% |
164,591
-1,845
| -1% | -$369K |
|
|
7
Biogen
BIIB
$30B
| $29.2M | 9.16% |
103,202
+5,679
| +6% | +$1.86M |
|
|
8
Exelixis
EXEL
$13.3B
| $21.1M | 6.63% |
+1,000,000
| New | +$18.6M |
|
|
SRGA
9
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $6.9M | 2.17% |
211,098
-2,338
| -1% | -$85.6K |
|
|
EGRX
10
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
| $6.01M | 1.89% |
107,773
+36,969
| +52% | +$1.82M |
|
|
IVC
11
DELISTED
Invacare Corporation
IVC
| $4.24M | 1.33% |
891,259
-10,453
| -1% | -$76.3K |
|
12
Travere Therapeutics
TVTX
$5.2B
| $3.33M | 1.04% |
137,203
-2,797
| -2% | -$51.4K |
|
13
NextCure
NXTC
$16.8M
| $208K | 0.07% |
2,577
-36
| -1% | -$3.16K |
|
|
14
AnaptysBio
ANAB
$1.58B
| – | – |
-10,890
| Closed | -$282K |
|
Similar funds
CIA
2
CIM
JFG
PIP
LRIC
GAMC
TIA
Krensavage Asset Management's Q3 2021 Portfolio in Review
As of Q3 2021, Krensavage Asset Management held 14 positions worth $319M, up 8.2% from $295M the previous quarter. Its ten largest holdings account for 98% of the portfolio.
Krensavage Asset Management's Q3 2021 filing shows 1 new, 3 increased, 9 reduced and 1 closed positions. Its largest new stake was Exelixis: 1,000,000 shares worth $21.1M. The largest sale was Alkermes, an estimated $6.97M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier.
- Krensavage Asset Management's largest Q3 2021 buy was Exelixis: 1,000,000 shares worth $21.1M.
- Krensavage Asset Management added most to Biogen in Q3 2021, an estimated $1.86M increase.
- Krensavage Asset Management's biggest Q3 2021 reduction was Alkermes, cutting an estimated $6.97M.
- Krensavage Asset Management fully exited AnaptysBio in Q3 2021, selling an estimated $282K.
- Krensavage Asset Management's ten largest holdings make up 98% of its $319M portfolio in Q3 2021.
- Krensavage Asset Management opened 1 new position and closed 1 in Q3 2021.
- Krensavage Asset Management's portfolio value rose 8.2% quarter-over-quarter to $319M.
Based on Krensavage Asset Management's 13F filing for Q3 2021, filed 16 Nov 2021.